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REVIEW
Abstract: Mechanism-based inhibition of cytochrome P450 (CYP) 3A4 is characterized by
NADPH-, time-, and concentration-dependent enzyme inactivation, occurring when some drugs
are converted by CYPs to reactive metabolites. Such inhibition of CYP3A4 can be due to the
chemical modification of the heme, the protein, or both as a result of covalent binding of
modified heme to the protein. The inactivation of CYP3A4 by drugs has important clinical
significance as it metabolizes approximately 60% of therapeutic drugs, and its inhibition
frequently causes unfavorable drug–drug interactions and toxicity. The clinical outcomes due
to CYP3A4 inactivation depend on many factors associated with the enzyme, drugs, and
patients. Clinical professionals should adopt proper approaches when using drugs that are
mechanism-based CYP3A4 inhibitors. These include early identification of drugs behaving
as CYP3A4 inactivators, rational use of such drugs (eg, safe drug combination regimen, dose
adjustment, or discontinuation of therapy when toxic drug interactions occur), therapeutic
drug monitoring, and predicting the risks for potential drug–drug interactions. A good
understanding of CYP3A4 inactivation and proper clinical management are needed by clinical
professionals when these drugs are used.
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Introduction
The human cytochrome P450 (CYP) 3A subfamily, includes CYP3A4, 3A5, 3A7
(Nelson et al 1996), and 3A43 (Domanski et al 2001). CYP3A4 is most abundant in
the human liver (~ 40%) and metabolizes more than 50% of clinically used drugs
(Shimada et al 1994; Rendic and Di Carlo 1997). Significant interindividual variability
in the expression and activity of CYP3A4 has also been observed (Shimada et al
1994; Thummel et al 1994; von Richter et al 2004; Watanabe et al 2004). Such a
substantial variability is considered to be a result of environmental, physiological,
and genetic factors (Gibson et al 2002). CYP3A4 is known to metabolize a large
variety of compounds varying in molecular weight from lidocaine
 (Mr = 234) to
cyclosporine (Mr = 1203) (Guengerich 1999; Rendic 2002). It is also subjected to
reversible and mechanism-based inhibition by a number of drugs. The latter involves
the inactivation of the enzyme via the formation of metabolic intermediates (MIs)
that bind tightly and irreversibly to the enzyme (Silverman 1988; Kent et al 2001).
Mechanism-based inactivation of CYP3A4 by drugs can be due to the chemical
modification of the heme, the protein, or both as a result of covalent binding of
modified heme to the protein (Osawa and Pohl 1989; Ortiz de Montellano and Correia
1995; Silverman 1998).
A mechanism-based inhibition of CYP3A4 is characterized by NADPH-, time-
and concentration-dependent enzyme inactivation and substrate protection (Ito et al
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1998b; Silverman 1998). Human liver microsomes, cDNA-
expressed enzyme, and hepatocytes are commonly used in
in-vitro models for the investigation of mechanism-based
inhibition of CYP3A4 (Silverman 1998). Important kinetic
parameters for mechanism-based inhibition such as KI (the
concentration required for half-maximum inactivation), kinact
(the rate constant of maximum inactivation at saturation,
analogous to Vmax), and partition ratio (Rmax, ratio of moles
of substrate activation per mole of enzyme inactivation) can
be determined using in vitro models. However, in vivo
animal and human studies are usually needed to explore the
clinical importance of CYP3A4 inactivation.
CYP3A4 inactivators such as delavirdine (Voorman et
al 1998), L-754,394 (Lightning et al 2000), 17α-
ethynylestradiol (Lin et al 2002), and midazolam (Schrag
and Wienkers 2001; Khan et al 2002) possibly bind
covalently
 to the CYP apoprotein and inactivate it. On the
other hand, certain CYP3A4 inactivators such as macrolides,
eg, erythromycin (Franklin 1991), glabridin (Kent et al
2002), and nelfinavir (Lillibridge et al 1998) bind the heme
and inactivate the enzyme. In addition, the reactive
intermediates of acetylenic compounds formed by several
CYPs have been known to alkylate the prosthetic
 heme group
as well as to bind covalently to the protein (Ortiz de
Montellano and Correia 1995). The aim of this review is to
highlight the clinical outcomes and management of
mechanism-based inhibition of CYP3A4.
Clinical outcomes of mechanism-
based inhibition of CYP3A4
Pharmacokinetic drug–drug interactions
Due to the key role of CYP3A4 in drug metabolism,
significant inactivation of this enzyme could result
 in marked
pharmacokinetic drug–drug
 interactions. The in vivo
inhibitory effect of a mechanistic inactivator is more
prominent after multiple dosing and lasts longer than that
of a reversible inhibitor (Lin and Lu 1998). The activated
species irreversibly
 alters the enzyme to remove it
permanently from the pool of active
 enzyme. Pharma-
cokinetic interactions often occur as a result of a change in
drug metabolism.
For example, diltiazem as a CYP3A4 inactivator has
been shown to potently inhibit the metabolism
 of a variety
of coadministered drugs including carbamazepine (Brodie
and Macphee 1986), cyclosporine (Brockmöller et al 1990;
Sadrieh and Thomas 1994), quinidine (Laganière et al 1996),
midazolam (Backman et al 1994), alfentanil (Ahonen et al
1996), nifedipine (Toyosaki et al 1988), and lovastatin (Azie
et al 1998). Inhibition of CYP3A by ritonavir explains,
at least in part, the remarkable elevation of blood
concentrations and area under the plasma concentration-
time curve (AUC) of concomitantly administered drugs
including rifabutin (Cato et al 1998), clarithromycin (Ouellet
et al 1998), ketoconazole (Hsu et al 1998), saquinavir (Hsu
et al 1998a), amprenavir (Sadler et al 2001; Goujard et al
2003), and nelfinavir (Hsu et al 1998; Kurowski et al 2002).
Pharmacokinetic studies have indeed revealed specific
interactions between erythromycin and cyclosporine
(Vereerstraeten et al 1987), cisapride (Jenkins and Gibson
1996; Michalets and Williams 2000; Kyrmizakis et al 2002),
pimozide (Rubinstein 2001), disopyramide (Ragosta et al
1989), lidocaine (Isohanni et al 1998, 1999), theophylline
(Hemsworth and Renton 1981), astemizole (Klausner 1999),
carbamazepine (Zitelli et al 1987; Tagawa et al 1989; Turner
and Renton 1989; Mota et al 1996), midazolam (Yeates et
al 1997), triazolam (Greenblatt et al 1998), alprazolam
(Yasui et al 1996), alfentanil (Bartkowski et al 1989),
mosapride (Katoh et al 2003), digoxin (Tsutsumi et al 2002),
and warfarin (Bussey et al 1985; Weibert et al 1989).
Inhibition of CYP3A by ritonavir partly explains the
remarkable elevation of blood concentrations and AUC of
concomitantly
 administered drugs that are extensively
metabolized by CYP3A4 and have intermediate (10–80 L/h)
to high (> 80 L/h) intrinsic clearance and significant first-
pass metabolism. These drugs include rifabutin (400%
increase) (Cato et al 1998), clarithromycin (77%) (Ouellet
et al 1998), ketoconazole (350%) (Hsu et al 1998),
saquinavir (5000%) (Hsu et al 1998a), amprenavir (210%)
(Sadler et al 2001), nelfinavir (152%) (Hsu et al 1998;
Kurowski et al 2002), ABT-378 (7700%) (Sham et al 1998),
and indinavir (380%) (Hsu et al 1998b). The large increase
in the plasma concentration of other protease inhibitors when
coadministered with ritonavir provides the basis of rational
dual protease inhibitor regimens, resulting in reduced doses
and less frequent dosage intervals.
The functional effects of CYP3A4 inactivation on the
pharmacokinetic behavior of the inhibitor itself or that of
coadministered drugs are complex and depend on factors
that are associated both with drugs and patients. The
downstream consequences (efficacy or toxicity) of CYP3A4
inhibition may or may not parallel the pharmacokinetic
alterations. Importantly, mechanism-based CYP3A4
inactivation causes long-term effects on drug
pharmacokinetics, as the inactivated CYP3A4 has to be
replaced by newly synthesized CYP3A4 protein.Therapeutics and Clinical Risk Management 2005:1(1) 5
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It is believed that the in vivo inhibitory effect of a
mechanistic inactivator is more prominent after multiple
dosing and lasts longer than that of a reversible inhibitor
(Lin and Lu 1998). The activated species irreversibly
 alters
the enzyme to remove it permanently from the pool of active
enzyme. Thus, the time-dependent
 inactivation of CYP3A
enzymes would result in nonlinear
 pharmacokinetics, as
exemplified by 50%–100% prolongation of the diltiazem
half-life in humans after chronic dosing compared with the
single-dose effects (Tsao et al 1990). Certainly, in addition
to enzyme inactivation, other mechanisms may also play a
role in the prolonged t1/2β. These include reversible inhibition
of CYP3A by diltiazem and its metabolites, interactions of
diltiazem with its metabolites, change of plasma protein
binding, and possible involvement of drug transporters such
as PgP. By investigating the pharmacokinetic interactions
between diltiazem and its metabolites, and with model PgP
inhibitors, identifying the contributions of these alternative
mechanisms is likely.
The extent
 of drug interaction due to CYP3A inactivation
will be time-dependent in both its onset and
 offset. For
example, erythromycin did not significantly inhibit the
clearance of alfentanil on the first day of coadministration
but
 produced a 25% decrease after 7 days (Bartkowski et al
1989).
 As the half-life for the onset of inactivation is
inversely
 proportional to the efficiency [kinact/(KI + [I])] of
inactivation, the delayed onset of inhibition by erythromycin
is a predictable property of a relatively weak inactivator.
The
 delayed termination of CYP3A inhibition is expected
to be independent
 of the inactivating drug and the extent of
inhibition. This time-dependent termination may explain the
serious adverse
 events associated with discontinuation of
the irreversible inactivator,
 mibefradil, and the need for
immediate initiation of alternative calcium-channel
 blocker
treatment (Mullins et al 1998; Prueksaritanont et al 1999).
A mibefradil washout period of 7–14 days is therefore
recommended.
Drug toxicities
Mechanism-based inactivation of CYP3A4 may cause
severe drug toxicity through the enhanced exposure to
coadministered drugs (Dresser et al 2000). For example,
when irreversible CYP3A4 inhibitors such as erythromycin
or clarithromycin are coadministered with terfenadine,
astemizole, or pimozide patients may experience Torsades
de pointes (a life-threatening ventricular arrhythmia
associated with QT prolongation) (Spinler et al 1995;
Dresser et al 2000; Michalets and Williams 2000).
Terfenadine is a CYP3A4 substrate that undergoes extensive
first-pass metabolism following oral administration (Honig
et al 1992; Jurima-Romet et al 1994). Normally, the
carboxylate metabolite of terfenadine is the principal
circulating entity in plasma, whereas unchanged terfenadine
is not present at measurable concentrations (Honig et al
1992, 1993). Furthermore, rhabdomyolysis has been
observed when simvastatin was combined with
erythromycin or ritonavir (Williams and Feely 2002).
Symptomatic hypotension may occur when mechanism-
based CYP3A4 inhibitors are combined with some
dihydropyridine calcium antagonists (Anderson and
Nawarskas 2001), as well as with the phosphodiesterase
inhibitor, sildenafil (Simonsen 2002). In addition, ataxia can
occur when carbamazepine is coadministered with
mechanism-based CYP3A4 inhibitors such as macrolide
antibiotics, isoniazid, verapamil, or diltiazem (Spina et al
1996; Patsalos et al 2002).
Mibefradil (Posicor) was launched for the long-term
therapy of patients with hypertension in the United States
in 1997, but was voluntarily withdrawn from the market in
June
 1998 due to potential toxic drug interactions. Severe
drug interactions of mibefradil (a mechanism-based
CYP3A4 inhibitor) have been reported with β-blockers
(Mullins et al 1998),
 digoxin (Siepmann et al 1995),
methylprednisolone (Varis et al 2000), verapamil (Mullins
et al 1998; Welker et al 1998), diltiazem (Mullins et al 1998;
Welker et al 1998), cyclosporine (Spoendlin et al 1998),
simvastatin (Schmassmann-Suhijar et al 1998; Welker et al
1998), and tacrolimus (Krahenbuhl et al 1998). For example,
4 cases of life-threatening cardiogenic shock have been
reported in patients taking mibefradil and β-blockers, who
also began taking dihydropyridine calcium channel blockers
(Mullins et al 1998).
 One case resulted in death, and the
other 3 survived episodes of cardiogenic shock with intensive
support of heart rate and blood pressure. Cases of myopathy,
including rhabdomyolysis, have been reported in patients
with hypertension taking simvastatin concomitantly with
mibefradil (Schmassmann-Suhijar et al 1998; Muck 2000).
These drug interactions often resulted in increased
plasma concentrations
 of coadministered drugs and/or
severe toxicity.
Immune responses
In addition to toxic drug–drug interactions, the formation
of drug-modified CYP3A can also play a role in the initiationTherapeutics and Clinical Risk Management 2005:1(1) 6
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of toxicity. The formed adduct can act as a hapten and induce
potential immune responses, leading to anti-CYP3A
autoantibody production. The formation of drug-CYP3A
adducts may thus be either nontoxic, or rarely fatal,
depending on the drugs, the kinetics of adduct formation
and degradation, other affected target proteins and organs,
and the pathological conditions of the patients (Chitturi and
George 2002). The reactivity of drug intermediates, the
subcellular localization of major protein targets, and the
primary interactions between metabolite and protein are
important determining factors of toxicity (Pumford and
Halmes 1997; Tornqvist et al 2002). Selective protein
covalent binding by drugs or metabolites has been associated
with target organ/tissue toxicity of drugs (Cohen et al 1997),
although the underlying mechanisms are still incompletely
known for most drugs.
Studies to reveal the role of drug reactive metabolites
and their protein-adducts (eg, modified CYP3A4) in the
mechanism of drug-induced idiosyncratic reactions are
lacking. Mostly the proposed mechanism is based on the
so-called hapten hypothesis, which requires drug
bioactivation, covalent binding to proteins followed by
uptake, antigen processing, and a polyclonal immune
response (Naisbitt et al 2001; Ju and Uetrecht 2002;
Pirmohamed et al 2002). The recently proposed “danger
hypothesis” by Pirmohamed et al (2002; Naisbitt et al 2003),
which hypothesizes that the immune system only responds
to danger signals, can be considered to be additive to the
hapten hypothesis. Thus, stimulation of an immune response
to a drug–protein adduct (signal 1) requires the presence of
co-stimulatory signals and cytokines (signals 2 and 3), which
propagate and determine the type of immune response. For
example, in acetaminophen (APAP) toxicity, covalent
binding of N-acetyl-p-benzoquinone (NAPQI) to proteins
(signal 1) may induce the production of nitric oxide
(signal 2) due to the activation of Kupffer cells, which then
scavenges superoxide to produce peroxynitrite (signal 3),
leading to protein nitration and tissue injury (Jaeschke et al
2002). The nature of the danger signal is poorly defined, as
some drug–protein adducts are not toxic in vivo.
Factors affecting the clinical outcomes
of mechanism-based CYP3A4 inhibition
The clinical outcomes due to CYP3A4 inactivation depend
on many factors associated with the enzyme, drugs, and
patients. The interindividual variations in enzyme activity,
polypharmacy, diseases, and genetic factors are all
potentially important factors affecting the outcomes of
mechanism-based inactivation of CYP3A4. In most cases,
there are remarkable interindividual variations in the
mechanism-based inactivation of CYP3A4 and subsequent
drug–drug interactions. This is mainly due to the significant
differences in the hepatic expression of CYP3A4, based on
both in vitro (35–100-fold) studies with a human liver bank
(Shimada et al 1994) and in vivo (20–50-fold) studies with
probe drugs such as erythromycin (Watkins 1994),
midazolam (Thummel et al 1994), and alfentanil (Kharasch
et al 2003). The expression of CYP3A can also be influenced
by inflammation and proinflammatory cytokines, which are
known to affect drug metabolism by downregulating or
upregulating expression of several CYPs, including the
CYP3A subfamily. However, it appears that there are no
marked age and gender differences in CYP3A4 expression
(Hunt et al 1992; Schmucker 2001; Meibohm et al 2002),
although 24%–36% higher activity in females has been
reported (Watkins et al 1989). Changes in liver size and
blood flow, renal function, and drug–protein binding and
distribution with aging may be significant variables that can
affect drug metabolism and elimination. Thus, age and
gender may be important factors determining the clinical
outcome of drug interactions involving CYP3A4
inactivation.
Intestinal CYP3A4 inactivation is also an important
factor modulating the clinical outcomes of CYP3A4
inactivation. For example, oral administration of
clarithromycin for one week resulted in an AUC ratio
(ie, pretreatment AUC/post-treatment AUC) for intravenous
midazolam of 0.33, but the ratio was 0.16 for oral midazolam
(Gorski et al 1998). This greater extent
 of interaction
observed after oral administration is consistent with the
intestinal availability of approximately 0.4 for midazolam
and
 a complete inactivation of intestinal CYP3A by
clarithromycin (Gorski et al 1998). Such a complete
inactivation of intestinal CYP3A is consistent with the
estimates of kinact and KI and the relatively high
concentrations of clarithromycin expected in the intestinal
lumen. The impact of inactivation
 of intestinal wall CYP3A
depends on the values of the inactivation parameters, the
residence time of the inhibitor at the site of
 CYP3A, and the
relative contribution of intestinal and hepatic metabolism
to the first-pass metabolism of a given drug.
The clinical consequences of mechanism-based
CYP3A4 inhibition depend upon additional factors. Such
factors include variations in concentration-time course,Therapeutics and Clinical Risk Management 2005:1(1) 7
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Table 1 Drugs as mechanism-based CYP3A4 inhibitors
kinact KI Interacting drugs
Drug (min
–1) (µM) (examples) Reference
Antibiotics Tinel et al 1989; Mayhew et al 2000
Clarithromycin 0.072 5.49 Cyclosporine, cisapride, etc
Erythromycin 0.08  46.6 Cyclosporine, cisapride, etc Chan and Delucchi 2000; Kanamitsu et al 2000;
Yamano et al 2001
Isoniazid  0.08 228 Triazolam, diazepam, etc Wen et al 2002
Troleandomycin 0.15 0.18 Carbamazepine, triazolam, etc Pessayre et al 1983; Miura et al 1989; Tinel et al 1989;
Chan and Delucchi 2000
Anticancer drugs
Irinotecan 0.06 24  Unknown Hanioka et al 2002
SN-38 0.10 26  Unknown Hanioka et al 2002
Tamoxifen 0.051 0.2  Theophylline, warfarin Zhao et al 2002
N-desmethyltamoxifen 0.08  2.6  Unknown Zhao et al 2002
Anti-HIV agents
Amprenavir 0.073  1.4  Ritonavir von Moltke et al 2000
Delavirdine 0.44  9.5  Rifampicin Voorman et al 1998
DPC 681 0.22 0.24 Unknown Luo et al 2003
L-754,394 1.62  7.5  Unknown Chiba et al 1995; Lightning et al 2000
Nelfinavir 0.18  5.6  Delavirdine, zidovudine, etc Lillibridge et al 1998
Ritonavir 0.078  0.07  Clarithromycin, ketoconazole, etc Koudriakova et al 1998; von Moltke et al 2000
Antihypertensive agents
Dihydralazine 0.05 35  Unknown Masubuchi and Horie 1999
Diltiazem 0.11  2.0 Cyclosporine, midazolam, etc Jones et al 1999; Ma et al 2000; Mayhew et al 2000;
Yeo and Yeo 2001
N-desmethyl diltiazem 0.027  0.77  Unknown Mayhew et al 2000
Mibefradil 0.40  2.3 Cyclosporine, verapamil, etc Prueksaritanont et al 1999
Nicardipine 2.0 0.6  Metoprolol, cyclosporine, etc Ma et al 2000
Verapamil 0.09  1.7  Midazolam, diltiazem, etc Ma et al 2000;  Yeo and Yeo 2001
Steroids and their modulators
17α-Ethynylestradiol 0.04 18 Imipramine, alprazolam, etc Lin et al 2002
Gestodene 0.40 46  Imipramine, alprazolam, etc Guengerich 1990
Mifepristone 0.089  4.7  Unknown He et al 1999
Raloxifene 0.16  9.9 Warfarin Chen et al 2002
Herbal constituents
Bergamottin 0.30  4.2 Grapefruit juice–drug interactions He et al 1998; Eagling et al 1999
6´, 7´-Dihydroxybergamottin 0.16 59 Grapefruit juice–drug interactions Schmiedlin-Ren et al 1997
Glabridin 0.14  7.0  Unknown Kent et al 2002
Oleuropein 0.09 22.2  Unknown Stupans et al 2001
Resveratrol 0.20 20  Unknown Chan and Delucchi 2000
Silybin 0.06 32 Indinavir, metronidazole Sridar et al 2004
Miscellaneous
Diclofenac 0.246 1640 Nateglinide, quinidine, etc Masubuchi et al 2002
Fluoxetine 0.017 5.26 Olanzapine, alprazolam Mayhew et al 2000
(-)-Hydrastine 0.23 110 Unknown Chatterjee and Franklin 2003
K11002 0.026  0.5  Unknown Jacobsen et al 2000
K11777 0.054  0.06  Unknown Jacobsen et al 2000
Midazolam 0.15  5.8  Diltiazem, verapamil, etc Khan et al 2002
Tabimorelin 0.08  4.7  Midazolam Zdravkovic et al 2003
Abbreviations: KI, the half-maximal rate of inactivation; kinact, the maximal rate constant of inactivation at saturation.Therapeutics and Clinical Risk Management 2005:1(1) 8
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plasma protein
 binding, atypical substrate kinetics for
CYP3A4, existence of multiple inhibitory metabolites,
partitioning from plasma to liver, rate-limiting active
transport of drug and inhibitor into the hepatocytes, intestinal
active efflux of drug, and inhibitor and extrahepatic
metabolism of drugs and inhibitors.
Clinical management of
mechanism-based inhibition of
CYP3A4
The inactivation of CYP3A4 by drugs has important clinical
implications since CYP3A4 metabolizes approximately 60%
of therapeutic drugs, and its inhibition frequently causes
unfavorable drug–drug
 interactions and toxicity. A good
understanding of CYP3A4 inactivation and proper clinical
management are needed by clinical professionals when these
drugs are used.
Identification of drugs causing
irreversible CYP3A4 inhibition
A number of drugs with widely differing structures and
therapeutic targets have been reported to be mechanism-
based inhibitors of CYP3A4 (Table 1). The identification
of drugs causing irreversible CYP3A4 inhibition and the
mechanisms involved are important in terms of rational use
of therapeutic drugs. Mechanism-based inhibition of
CYP3A4 can decrease a drug’s first-pass clearance in the
liver and greatly alter the kinetic behavior. Moreover, the
decrease in functional catalytic activity of the damaged CYP
can lead to enhanced exposure of other drugs that are
normally cleared by CYP3A4, thus setting the stage for
potential drug–drug interactions. It is therefore not surprising
that during drug development new compounds that are
potent CYP3A4 inhibitors are regarded with high skepticism
and often withdrawn from further development.
Early and timely identification of candidate drugs that
inactivate CYP3A4 is important in drug development, as
this can save large expenditures in time and money. In cases
where new drugs have already been launched, and where a
large population of patients has been exposed to the drug,
severe interactions and even fatal toxicity may occur.
Therefore, lessons should be learned from such cases
(eg, mibefradil) where a drug was withdrawn from the
market due to an unacceptable risk of potentially dangerous
drug–drug interactions resulting from CYP3A inactivation.
With the current techniques, it is increasingly possible to
predict which new drugs will be associated with the
formation of reactive metabolites and CYP3A inactivation.
By screening drug candidates for possible formation of
reactive metabolic intermediates (MIs) that inhibit CYP3A4
in an irreversible manner, and by establishing structure-
activity relationships, it is possible to identify and eliminate
such chemicals at an early stage of development. The
application of genomic and proteomic approaches to the
study of drug–CYP interactions, as well as the use of
heterogeneous expression systems for specific CYPs
including CYP3A4, has the potential to lead to a more
effective screen due to a high-throughput capacity.
So far, the identified clinically important mechanism-
based CYP3A4 inhibitors include antibiotics (eg,
clarithromycin, erythromycin, and isoniazid), anticancer
agents (eg, irinotecan and tamoxifen), anti-HIV agents (eg,
ritonavir and delavirdine), antihypertensives (eg, verapamil
and diltiazem), and steroids and their modulators (eg,
gestodene and mifepristone). Most of these CYP3A4
inactivators are also substrates and inducers of CYPs (in
particular CYP3A4). The drugs that inactivate CYP3A4
often possess a number of structural similarities such as a
tertiary amine function, a furan ring, and an acetylene
functional group. It appears that the chemical properties of
a drug critical for CYP3A4 inactivation include: (1) being a
CYP substrate; (2) formation of reactive metabolites; (3)
preponderance of CYP inducers; and (4) being a P-
glycoprotein (PgP) substrate.
Rational use of drugs as mechanism-
based CYP3A4 inhibitors
Several drugs (eg, mibefradil) that have been identified as
CPY3A4 inactivators have been withdrawn from the market
due to reported toxic drug–drug toxicities. However, a
number of drugs that behave as mechanism-based CYP3A4
inhibitors are still in use by clinical doctors. Caution should
be taken when these drugs are used, particularly when used
in combination with other drugs that are CYP3A4 substrates
and have narrow therapeutic indices.
Mechanism-based CYP3A4 inhibitors that have been
reported to cause significantly increased systemic exposure
of coadministered drugs and/or severe drug toxicity should
be avoided. For example, it is known that erythromycin can
cause Torsades de pointes when coadministered with
terfenadine, cisapride, or astemizole (all CYP3A4
substrates) (Spinler et al 1995; Dresser et al 2000; MichaletsTherapeutics and Clinical Risk Management 2005:1(1) 9
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and Williams 2000), and should therefore be avoided in these
combinations.
In some instances, proper dose adjustment or alternative
drugs may be needed when a CYP3A4 inactivator is
combined with another drug. For example, isoniazid, a
mechanism-based CYP3A4 inhibitor (Wen et al 2002),
markedly increased serum phenytoin concentrations, with
resultant toxicity in some patients (Kutt et al 1968; Miller
et al 1979). Isoniazid also potentiated acetaminophen
hepatotoxicity (Crippin 1993; Nolan et al 1994). One case
of increased warfarin toxicity (at 10 mg/day) including
increased prothrombin time,
 hematuria, and bleeding gums
caused by isoniazid has also been reported (Self et al 1999).
Such interactions will require a reduced dose of
coadministered drugs or replacement of drugs with similar
efficacy while maintaining the isoniazid therapy.
Role of therapeutic drug monitoring
Monitoring plasma concentrations of concurrently
administered drugs that are CYP3A4 substrates and/or have
narrow therapeutic indices, and observing for signs of
clinical toxicity are necessary for the early identification of
potential drug–drug interactions and subsequent toxicities.
Tamoxifen, a nonsteroidal antiestrogen used for adjuvant
chemotherapy of all stages of hormone-dependent breast
cancer, is a potent mechanism-based CYP3A4 inhibitor
(Zhao et al 2002). However, clinical data on tamoxifen–
drug interactions are scant. A potential life-threatening
interaction (Lodwick et al 1987; Ritchie and Grant 1989;
Tenni et al 1989) may occur when tamoxifen is combined
with warfarin, a substrate for CYP2C9, 2C19, and 3A4
(Komatsu et al 2000). Prothrombin time doubled in a few
cases and subdural hematoma developed. It is believed that
CYP inhibition is likely to be the major mechanism for this
interaction, while displacement of protein binding may just
play a minor role. Thus, the plasma concentration of warfarin
and prothrombin time should be carefully monitored when
tamoxifen is coadministered with warfarin.
Herbal components may also behave as mechanism-
based CYP3A4 inhibitors. Silybin, the major constituent of
milk thistle (Sylybum marianum), is a mechanism-based
inhibitor of CPY3A4 (Sridar et al 2004). Treatment of milk
thistle at 175 mg (equivalent to silymarin 153 mg) 3 times
per day for 3 weeks caused a 9% and 25% reduction in the
AUC and mean trough level of indinavir, respectively (C8,
the concentration at 8 hours) in healthy volunteers (Piscitelli
et al 2002). Therefore, monitoring plasma indinavir
concentrations may be required when patients also take
milk thistle.
Predicting risks for drug–drug
interactions involving CYP3A4
inactivation
It may be necessary to assess the clinical risks by predicting
qualitatively and quantitatively drug–drug interactions
involving CYP3A4 inactivation. Generally, it can be
anticipated that the inactivation of CYP3A4 by various drugs
would increase the bioavailability
 of coadministered drugs
that are primarily metabolized by CYP3A4, due to intestinal
and/or hepatic inhibition of CYP3A4. Compared with
reversible inhibition of CYP3A4, mechanism-based
inhibitors of CYP3A4 more frequently cause pharma-
cokinetic-pharmacodynamic drug–drug
 interactions, as the
inactivated CYP3A4 has to be replaced by newly
synthesized CYP3A4 protein. The resultant drug interactions
may lead to adverse drug effects, including some fatal events.
The accurate interpretation and extrapolation of in vitro
interaction data requires a good understanding of
pharmacokinetic principles. If the elimination of a drug is
mainly by the liver, the total clearance is approximately equal
to the hepatic clearance. For low-clearance drugs, a
metabolism-based drug interaction will result in an almost
proportional decrease in their clearance. On the other hand,
if the intrinsic clearance is high, then the hepatic clearance
is limited by the hepatic blood flow. Thus, for high-clearance
drugs, a decrease in the intrinsic clearance caused by drug
interaction has little effect on their hepatic clearance.
However, the in vitro inhibitory potency of mechanism-
based CYP3A4 inhibitors does not necessarily translate
directly into relative extents of inhibition in vivo.
Determination of in vitro kinetic parameters is essential
for the prediction of drug metabolism by a particular CYP
in vivo. The apparent KI values for competitive inhibition
determined in vitro, together with its relationship to unbound
plasma concentrations of the inhibitor achieved with
therapeutic doses in vivo, can be used as a rough guide to
predict the possibility of a significant in vivo drug interaction
(Ito et al 1998a, 1998b). Relating the in vitro results to in
vivo pharmacokinetics is not straightforward. Generally, to
quantitatively predict the
 degree of interaction observed in
clinical cases,
 it is necessary to investigate the correlation
between in vitro
 inhibitory potency of the inhibitor and in
vivo inhibition, taking into account the distribution of theTherapeutics and Clinical Risk Management 2005:1(1) 10
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inhibitor into the liver,
 and extrapolation of data from animal
studies (Yamano et al 2001).
Conclusions and future
perspectives
The broad substrate selectivity makes CYP3A4 susceptible
to relatively frequent reversible or irreversible (mechanism-
based) inhibition by a wide variety of drugs. Irreversible
inhibition of CYP3A4 due to enzyme inactivation or
complexation occurs when some therapeutic drugs are
converted by CYPs to reactive metabolites capable of
covalently binding to CYP3A4 protein or heme moiety.
Mechanism-based inhibition of CYP3A4 is characterized
by NADPH-, time-, and concentration-dependent enzyme
inactivation. A number of therapeutic drugs have been
identified as mechanism-based CYP3A4 inhibitors.
Due to the key role of CYP3A4 in drug metabolism,
inactivation of this enzyme could result
 in marked
pharmacokinetic drug–drug
 interactions and/or toxicities.
The clinical outcome of any drug–drug interaction due to
CYP3A4 inactivation depends on a number of factors that
are associated with both the administered drugs and patients,
and the pharmacodynamic consequences may or may not
closely follow pharmacokinetic alterations. Since many
mechanism-based CYP3A4 inhibitors are also inducers of
CYPs, and because enzyme inactivation is significantly
affected by drug exposure time, the clearance of
coadministered drugs may be increased or decreased in vivo,
depending on the interplay between substrate, inhibitor,
inducer, and CYP3A4. Thus, detailed studies are often
needed to characterize these drugs and their potential drug–
drug interactions.
Clinicians should adopt proper strategies when using
drugs that are mechanism-based CYP3A4 inhibitors. Early
identification of drugs behaving as CYP3A4 inactivators
and the mechanism involved is important. If these drugs
have to be used in some instances, rational use of such drugs
becomes necessary, including the use of a safe drug
combination regimen, dose adjustment, and discontinuation
of therapy when toxic drug interactions occur. When
combined with drugs with narrow therapeutic indices, the
monitoring of plasma drug concentrations and observing
of potential toxicities should be conducted. Predicting the
risks for potential drug–drug interactions following proper
pharmacokinetic principles and in vitro–in vivo
extrapolation is likely. A good understanding of CYP3A4
inactivation and proper clinical management are needed by
clinical professionals when these drugs are used.
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